AI-Generated Content Strategy — Building Review Into a "Fast to Make" Era── The speed of mass production, and the wall of regulation. A design that makes both work, drawn from the pharma content floor.

01What "Fast to Make" Actually Changed

First, look precisely at what generative AI brought to pharma marketing content. What changed is not only "how fast we make it." As speed rose, the volume, the variety, and even who does the making changed with it. Work that specialist creators once produced one piece at a time can now be tried in dozens of variations, on the spot, by the person in charge.

This shift is a large opportunity. Tailoring physician materials by therapeutic area. Rewriting patient explanations to match each reader's level of understanding. Things once abandoned for lack of budget and time are now within reach. Yet that same speed is also the speed of risk. Wrong content can be made in bulk, just as fast.

So the question this time is framed like this: without giving up the speed of generative AI, how should we restructure the very way content is made, so that regulation and trust are protected? Not slowing down to buy safety, not sacrificing safety for speed — we look for a third path.

02Three Traps Hidden in Mass Production

When you mass-produce content with generative AI, three dangers stand out on the pharma floor. Each is born from the underside of "fast to make."

What the three share is this: AI optimizes for "plausibility," not "correctness." Easy to read, persuasive, convincing-looking — which is exactly why errors are hard to spot. The faster you go, the higher the chance of missing these "plausible mistakes." From the next section, we build a wall against each one.

03The Wall That Does Not Move — the Pharmaceutical Act, Exactly

However fast generative AI becomes, the Pharmaceutical Act does not change. This is a foundation that cannot be left vague, so we check the articles precisely. Three provisions sit at the center of drug advertising.

Cite the wrong article number and that alone erodes trust. Exaggerated advertising is Article 66, unapproved advertising is Article 68, information provision is Article 68-2 — this is a foundation worth memorizing outright. When you have generative AI write content, a person must always watch which of these three walls it is drawing near.

04The Guidelines and the Fair Advertising Standards — the Same Yardstick for Generated Work

Below the law sit yardsticks closer to practice. There is the Ministry of Health, Labour and Welfare's Sales Information Provision Guidelines (= the Guidelines on Sales Information Provision Activities for Prescription Drugs, 2018) and the Standards for Fair Advertising of Drugs and the like (= a yardstick for advertising expression, issued as a notice by the Director of the Compliance and Narcotics Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW). The fact that content was made by AI does not loosen these yardsticks in the slightest. Whether a person or an AI writes it, the standard applied is the same.

What matters here is the obvious fact that judgment rests on "what is written," not "who made it." The idea of going easy because it is AI-made does not hold. If anything, the more you mass-produce, the more you need machinery to hold each piece to the same rigor. The World Health Organization's Ethical Criteria for Medicinal Drug Promotion (= an international yardstick that drug promotion must observe, 1988) likewise demands accuracy, fairness, and verifiability, and generated work is no exception.

05Human-in-the-Loop — Placing Review Inside the Speed

So how do you design it? The key is human-in-the-loop (= a design that always inserts human judgment partway through the AI's processing). You do not let the AI make it all the way and then fix the result afterward. You place, partway through the making, a checkpoint where a person pauses and confirms. Do not kill the speed, but route it through human judgment. This order is what counts.

Concretely, divide content into three stages, and set a checkpoint at each.

• Entry (prompt design) — At the stage of deciding what to have the AI write, hand it, in advance and as a frame, the approved indications, the phrasing you may use, and the phrasing you forbid. Give no frame here, and the AI freely "inflates."
• Middle (checking the first draft) — A person cross-checks the generated draft against primary sources. Confirm that every figure, indication, and citation matches the approved content and the original. This is the largest checkpoint.
• Exit (final review) — Put it on the formal material-review process. Judge whether it may be published, by the yardsticks of the Pharmaceutical Act, the Sales Information Provision Guidelines, and the Fair Advertising Standards. Being AI-made is no exemption.

These three checkpoints are not there to slow speed down. They are the structure that lets you spend speed safely. Because the checkpoints exist, the person in charge can mass-produce with confidence. Only when there is a mechanism to stop can you press the accelerator.

06Building In the Guardrails Ahead of Time

Rely on human eyes alone at the checkpoints, and you cannot keep up with the speed of mass production. So we build guardrails (= mechanisms set up in advance to keep the AI from leaving the frame) into the design. Before a person reads everything, screen out what can be screened mechanically. The following four are design principles that work in practice.

Guardrails do not strip the person in charge of freedom. Leave the mechanical catching of missteps to machinery, and people can concentrate on the more essential judgment — "will this phrasing reach a physician without misunderstanding?" Simple deviations to the mechanism, subtle judgments to people. This division of labor is the base for running review in the age of mass production.

07One Asset, Tailored to Each Audience — Multi-Audience Optimization

Generative AI's speed becomes most valuable when you take the same substance and tailor it to the audience. Physicians, pharmacists, and patients need different information, and reach for different words. Once, a single pamphlet went to everyone; now you can issue a separate version for each audience. But even when you tailor, the fact you build on must be one.

The fear in tailoring lies in the fact drifting apart across audiences. It will not do for the same drug's efficacy to leave a different impression in the physician version and the patient version. So in multi-audience optimization, you place "one approved fact" at the center and vary only the expression to suit the audience. Do not change the substance; change the delivery. Generative AI shows its power precisely in this "translation of delivery."

08Measure the Effect, Protect the Brand

Once you can mass-produce, the next urge is to measure "which one worked." Open rates, dwell time, physician response — the data is there. But effect measurement for pharma content carries a caution absent from ordinary marketing. Strong short-term response can damage the long-term brand.

A slightly "inflated" phrasing, for instance, may draw a better response in the moment. But once it is deemed exaggerated even a single time, the trust you stacked up collapses in an instant. A drug is a "credence good (= a good whose quality is hard to verify beforehand and that rests on trust)." So in effect measurement you must always look, alongside the response numbers, at whether that phrasing is eroding the brand's trust. Losing to a breach of trust what you gained through speed defeats the whole purpose.

09Connections to Other Chapters on This Site

This time, reading alongside the following chapters deepens the understanding.

• AI Marketing Vol. 1 — Marketing Redefined — the whole map of why the content element changes most fiercely.
• Material Review Series — the practice of the review that finally catches the generated work. It is the "exit" of human-in-the-loop.
• Nichi Nichi Kore Kōjitsu (Everyday a Good Day) — essays that draw review as a human undertaking: delivering the finding, handling anger and expectation.

Generative AI made pharma content something you can make "fast, in bulk, and per audience." This is a large opportunity. But that same speed carries the old dangers — exaggeration, off-label, unsupported assertion — at a new scale. Not slowing to buy safety, not discarding safety for speed. Build review into the speed — hand over approved information at the entry, cross-check against primary sources in the middle, review formally at the exit. Leave simple deviations to the guardrails, and let people carry the subtle judgments.

The Pharmaceutical Act does not move because AI grew fast. Article 66's exaggeration, Article 68's unapproved, Article 68-2's information provision — these walls gain meaning precisely in the age of mass production. Design generative AI not as a tool for evading regulation, but as a base that deepens trust while holding the regulation intact. Use the power to make things fast in order to protect the brand — the most fragile good of all. That is the core of AI-generated content strategy. Next time, we move to predictive marketing that reads the customer's "what they want next" in advance, and the ethical boundary around it.